康华生物: 关于筹划公司控制权变更进展暨复牌的公告

Group 1 - The company, Chengdu Kanghua Biological Products Co., Ltd., has announced a suspension of trading due to the planned change of control involving its controlling shareholder, Wang Zhentao, which carries uncertainties [1][2] - The stock will resume trading on July 21, 2025, following the completion of the necessary agreements and regulatory approvals [3] - A share transfer agreement has been signed, where Wan Kexin Biological Technology Partnership intends to acquire a total of 28,466,638 shares from Wang Zhentao, Aokang Group, and Jinan Kangyue Qiming Investment Partnership, with a transfer price of 65.0266 yuan per share, totaling approximately 1.851 billion yuan [1][2] Group 2 - After the completion of the share transfer and voting rights delegation, Wan Kexin Biological will hold the voting rights of the company, effectively changing the actual controller from Wang Zhentao to no actual controller [2] - The company will continue to monitor the progress of the share transfer and ensure compliance with relevant laws and regulations, fulfilling its information disclosure obligations [3]